Literature DB >> 15578276

Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides.

Xudong Huang1, Craig S Atwood, Robert D Moir, Mariana A Hartshorn, Rudolph E Tanzi, Ashley I Bush.   

Abstract

Nucleation-dependent protein aggregation ("seeding") and amyloid fibril-free formation of soluble SDS-resistant oligomers ("oligomerization") by hydrophobic interaction is an in vitro model thought to propagate beta-amyloid (Abeta) deposition, accumulation, and incur neurotoxicity and synaptotoxicity in Alzheimer's disease (AD), and other amyloid-associated neurodegenerative diseases. However, Abeta is a high-affinity metalloprotein that aggregates in the presence of biometals (zinc, copper, and iron), and neocortical Abeta deposition is abolished by genetic ablation of synaptic zinc in transgenic mice. We now present in vitro evidence that trace (<or=0.8 microM) levels of zinc, copper, and iron, present as common contaminants of laboratory buffers and culture media, are the actual initiators of the classic Abeta1-42-mediated seeding process and Abeta oligomerization. Replicating the experimental conditions of earlier workers, we found that the in vitro precipitation and amyloidosis of Abeta1-40 (20 microM) initiated by Abeta1-42 (2 microM) were abolished by chelation of trace metal contaminants. Further, metal chelation attenuated formation of soluble Abeta oligomers from a cell-free culture medium. These data suggest that protein self-assembly and oligomerization are not spontaneous in this system as previously thought, and that there may be an obligatory role for metal ions in initiating Abeta amyloidosis and oligomerization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15578276     DOI: 10.1007/s00775-004-0602-8

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  50 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

3.  Treatment of Alzheimer's disease with clioquinol.

Authors:  B Regland; W Lehmann; I Abedini; K Blennow; M Jonsson; I Karlsson; M Sjögren; A Wallin; M Xilinas; C G Gottfries
Journal:  Dement Geriatr Cogn Disord       Date:  2001 Nov-Dec       Impact factor: 2.959

4.  Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains.

Authors:  S W Suh; K B Jensen; M S Jensen; D S Silva; P J Kesslak; G Danscher; C J Frederickson
Journal:  Brain Res       Date:  2000-01-10       Impact factor: 3.252

5.  Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease.

Authors:  A E Roher; M O Chaney; Y M Kuo; S D Webster; W B Stine; L J Haverkamp; A S Woods; R J Cotter; J M Tuohy; G A Krafft; B S Bonnell; M R Emmerling
Journal:  J Biol Chem       Date:  1996-08-23       Impact factor: 5.157

6.  Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions.

Authors:  D A Loeffler; J R Connor; P L Juneau; B S Snyder; L Kanaley; A J DeMaggio; H Nguyen; C M Brickman; P A LeWitt
Journal:  J Neurochem       Date:  1995-08       Impact factor: 5.372

7.  Characterization of beta-amyloid peptide from human cerebrospinal fluid.

Authors:  C Vigo-Pelfrey; D Lee; P Keim; I Lieberburg; D B Schenk
Journal:  J Neurochem       Date:  1993-11       Impact factor: 5.372

8.  Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer's disease.

Authors:  Avi L Friedlich; Joo-Yong Lee; Thomas van Groen; Robert A Cherny; Irene Volitakis; Toby B Cole; Richard D Palmiter; Jae-Young Koh; Ashley I Bush
Journal:  J Neurosci       Date:  2004-03-31       Impact factor: 6.167

9.  Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution.

Authors:  H LeVine
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

10.  Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging.

Authors:  M Enya; M Morishima-Kawashima; M Yoshimura; Y Shinkai; K Kusui; K Khan; D Games; D Schenk; S Sugihara; H Yamaguchi; Y Ihara
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

View more
  73 in total

1.  Role of zinc in human islet amyloid polypeptide aggregation.

Authors:  Jeffrey R Brender; Kevin Hartman; Ravi Prakash Reddy Nanga; Nataliya Popovych; Roberto de la Salud Bea; Subramanian Vivekanandan; E Neil G Marsh; Ayyalusamy Ramamoorthy
Journal:  J Am Chem Soc       Date:  2010-07-07       Impact factor: 15.419

2.  Early post-natal iron administration induces astroglial response in the brain of adult and aged rats.

Authors:  Liana Lisboa Fernandez; Maria Noêmia Martins de Lima; Felipe Scalco; Gustavo Vedana; Clívia Miwa; Arlete Hilbig; Mônica Vianna; Nadja Schröder
Journal:  Neurotox Res       Date:  2010-12-17       Impact factor: 3.911

3.  Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors.

Authors:  Haitao You; Shigeki Tsutsui; Shahid Hameed; Thomas J Kannanayakal; Lina Chen; Peng Xia; Jordan D T Engbers; Stuart A Lipton; Peter K Stys; Gerald W Zamponi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 4.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

5.  Iron, copper, and iron regulatory protein 2 in Alzheimer's disease and related dementias.

Authors:  Shino Magaki; Ravi Raghavan; Claudius Mueller; Kerby C Oberg; Harry V Vinters; Wolff M Kirsch
Journal:  Neurosci Lett       Date:  2007-03-03       Impact factor: 3.046

Review 6.  Oxidation of therapeutic proteins and peptides: structural and biological consequences.

Authors:  Riccardo Torosantucci; Christian Schöneich; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

7.  Human brain myelination and amyloid beta deposition in Alzheimer's disease.

Authors:  George Bartzokis; Po H Lu; Jim Mintz
Journal:  Alzheimers Dement       Date:  2007-04       Impact factor: 21.566

8.  Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1-42) oligomer assembly.

Authors:  Harry LeVine; Qunxing Ding; John A Walker; Randal S Voss; Corinne E Augelli-Szafran
Journal:  Neurosci Lett       Date:  2009-08-05       Impact factor: 3.046

Review 9.  Twenty years of metallo-neurobiology: where to now?

Authors:  Ashley I Bush; Cyril C Curtain
Journal:  Eur Biophys J       Date:  2007-11-10       Impact factor: 1.733

10.  Aroylhydrazones constitute a promising class of 'metal-protein attenuating compounds' for the treatment of Alzheimer's disease: a proof-of-concept based on the study of the interactions between zinc(II) and pyridine-2-carboxaldehyde isonicotinoyl hydrazone.

Authors:  Daphne S Cukierman; Elio Accardo; Rosana Garrido Gomes; Anna De Falco; Marco C Miotto; Maria Clara Ramalho Freitas; Mauricio Lanznaster; Claudio O Fernández; Nicolás A Rey
Journal:  J Biol Inorg Chem       Date:  2018-08-25       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.